January 23rd, 2012, by David Pascoe | in the news, IPL
An article in this Weekend’s West Australian highlighting the dangers of IPL Treatments from untrained operators. This article is a reminder of the dangers of IPL in the wrong hands. Other warnings are, sadly, easy to find.
Finding the right practitioner to treat you with IPL is not an easy task. This is a real dilemma for rosacea sufferers as we do know that IPL is Excellent for Rosacea.
Woman scarred by skin treatment
Kate Bastians, The West Australian, Updated January 21, 2012, 3:00 am
Perth women are being left with scars and severe burns caused by amateur beauty therapists performing a popular hair removal and skin treatment without proper training.
A Joondalup woman has told how her chest resembles a chequerboard of excruciatingly painful burns after receiving Intense Pulsed Light treatment for sun spots two weeks ago.
…
The woman, who received the treatment from a woman who had set up a home business, feared she would be scarred for life and wanted to warn others about the complications that may arise from the treatment.
…
The WA Australian Medical Association and the Cosmetic Physicians Society of Australasia have called on the Health Department to introduce standards for the booming IPL industry, which is unregulated.
…
The Department of Consumer Protection received 21 inquiries and 10 complaints about IPL last year, which included reports of burns and scarring. That was up from 15 inquiries and one complaint in 2010.
Chris Goodwin, director of the Australian College of Beauty Therapy in Perth, said people were buying cheap IPL machines off the internet and using them on people without appropriate training.
"They think it sounds like a great money-making exercise and they get two days training and that’s it," she said. "There are too many cases where people are getting badly burnt and I think the Health Department needs to act."
AMA WA vice-president Richard Choong said there had been an increase in reports of people receiving burns from IPL treatment as it became more readily available.
Related Articles
January 22nd, 2012, by David Pascoe | clinical trials, galderma, metrogel
A recently posted clinical trial suggests that Taro Pharmaceuticals is readying to gain approval to market Generic Metrogel 1%. Currently Generic Metrogel is only available in 0.75% strength.
Taro Pharmaceuticals in fact already markets a generic form of Metrogel – Metronidazole Gel USP, 0.75%
When the patent covering Metrogel 0.75% expired, Galderma changed the formulation, increased the concentration of metronidazole to 1% and now produces the best-known rosacea treatment, Metrogel 1%.
This is good news for rosacea suffers, who can only benefit from competition in the rosacea treatment staples market. Often rosacea sufferers come away from their first visit to the doctor and pharmacist with one thought – Why is this Metrogel so expensive?
Trial CT01513863 is listed to compare Taro Pharmaceutical’s Generic Metronidazole 1% Gel with Galderma’s Metrogel 1% (and also placebo).
Clinical Trial NCT01513863
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea (MTZG)
A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multi-Site Clinical Study to Compare the Bioequivalence of Two Metronidazole 1% Topical Gel Formulations in Patients With Moderate to Severe Rosacea
Arm 1
Metronidazole Topical Gel 1%: Experimental
Intervention: Drug: Metronidazole Topical Gel 1%
Arm 2
Metronidazole Topical Gel 1% (Metrogel ): Active Comparator
Intervention: Drug: Metronidazole Topical Gel 1% (Metrogel)
Arm 3
Placebo: Placebo Comparator
Intervention: Drug: Placebo
Related Articles
January 19th, 2012, by David Pascoe | galderma, patents
While us in the rosacea world might consider products that are expensive while they are covered by exclusive patents, we are small fry in the drug market at large.
Patents are due to shortly expire for Pfizer’s Liptor and Lilly’s Zyprexa. Lilly can expect a $3bn drop in revenue just from generic forms of Zyprexa becoming available. Pfizer is thought to have earned around $7.8bn from US sales in the 12 months to September 2011.
By comparison, Oracea is thought to have generated sales of $260m in 2011 for Galderma. So even though Oracea is very expensive compared to 50mg of generic doxycycline, Oracea itself being protected by a long-lasting patent is still small-fry compared to giants like Liptor and Zyprexa.
Metrogel 1% is also protected by patents owned by Galderma, so don’t expect to see similar formulations to Metrogel 1% becoming available before they expire. Galderma will naturally enjoy exclusive marketing and write their own pricing of Sansrosa/CDCD07805/47 should that become available as well.
Patent expiries and emerging pharma markets to fuel $100bn generics growth
Published: 17/01/2012
The global generics market is expected to reach $231bn by 2017, led by patent expiries on blockbuster drugs and the growth of emerging markets, according to a new report.
Analysts at Frost & Sullivan also highlighted impact of government cost-cutting measures and say sales of generics will grow by over $100bn, up from the $123.85bn generated in 2010.
Their Generic Pharmaceuticals Market – A Global Analysis report that generics manufacturers will benefit from the patent expiries of blockbusters, with revenues worth $150bn.
Heading up these are Pfizer’s Lipitor, which lost its patent protection in the US at the end of 2011 and is due to lose exclusivity in Europe in May 2012.
Lilly will also be hit hard by generic competition to its antipsychotic Zyprexa (olanzapine), with revenues of the drug expected to fall by $3bn for 2012.
Related Articles
January 18th, 2012, by David Pascoe | metrogel
Galderma have announced that Metrogel 1% will now be available in a 55gm Pump. Galderma are citing the benefits of a better looking dispenser, minimizing waste, easier compliance with prescribing instructions and “facilitating product handling”. Galderma received FDA approval for Metrogel 1% Pump in October 2011.
Metrogel 1% Pump is now available on prescription in pharmacies across the U.S.
As we know, the Metronidazole market is awash with choices; Metrogel 1%, Rozex, Metrolotion, Metrocream and Noritate – and now Metrogel 1% Pump.
Galderma Announces Availability of New Metrogel(R) 1% Pump Dispenser for the Treatment of Papulopustular Rosacea
Pump Delivery Provides Consistent Dosing, Minimizes Waste and May Help Increase Patient Compliance
FORT WORTH, TX–(Marketwire -01/17/12)- Galderma Laboratories, L.P. today announced the availability of a new pump dispenser design for MetroGel® (metronidazole) Gel, 1%, the most powerful strength of topical metronidazole available in a gel to treat the inflammatory lesions (bumps and blemishes) associated with rosacea. The MetroGel® 1% Pump, which the U.S. Food and Drug Administration approved in October 2011, is now available by prescription to patients in pharmacies nationwide.
Results from a new survey of 207 physician-diagnosed rosacea patients, ages 25 to 65, found 69 percent of patients prefer a pump over a tube. Patients in the survey also felt the pump was more aesthetically pleasing and reported the pump delivery facilitates product handling and storage and minimizes waste. Additionally, patients thought the pump delivery would help them to follow their doctor’s instructions on product usage.
Related Articles
January 6th, 2012, by David Pascoe | in the news
Happy New Year to everyone who reads Rosacea Support !
As we start 2012 lets look briefly at what was popular in the last year.
Most popular posts in 2011
Following are the 5 most popular posts in 2011 for new comments. All of these posts have been on the blog for a couple of years, proving that they are still interesting after all this time.
- How to Cure a Red Face (facial erythema or redness) 189 comments
- How to cure a Red Swollen Nose 114 comments
- What is the Best Moisturizer for Rosacea ? 118 comments
- Just How do you Kill Demodex Mites ? 629 comments
- Clinique Redness Solutions: user reviews 95 comments
New Posts
There were 93 new posts written in 2011 whereas Rosacea News put up 108 new posts during 2010.
Search Terms
Most new visitors came to the blog searching via Google. You may be interested to know that the most popular search terms were;
- rosacea pictures
- rosacea support
- prosacea
- demodex mites
- zenmed reviews
- rosacea treatments over the counter
- ocular rosacea
This list may be surprising to you perhaps, especially if you have never yourself looked for information on these topics.
Even though these were by far the most popular search terms, there are plenty more ! I am often surprised by the hugely varying array of things that people are searching for on the internet. The full list of search terms seems to never end!
Traffic
Overall in 2011 there were around 976,666 Visits, 739,129 Unique Visitors, and 1,927,057 Pageviews. Those numbers all don’t mean too much – but hopefully show that the site contains stuff that people actually want to read.
Looking Forward
I wish everyone a great 2012, with continuing success is everyones’ battle against rosacea.
Even more, I wish for more treatments options, and easily accessible knowledge about existing options.
Thanks for your support of the site,
David Pascoe, January 2012.
